Jubilant Pharmova Ltd
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]
- Market Cap ₹ 9,079 Cr.
- Current Price ₹ 570
- High / Low ₹ 627 / 277
- Stock P/E 248
- Book Value ₹ 340
- Dividend Yield 0.88 %
- ROCE 3.13 %
- ROE -6.89 %
- Face Value ₹ 1.00
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -3.53% over past five years.
- Company has a low return on equity of 5.80% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4,270 | 5,132 | 5,762 | 5,751 | 5,749 | 5,861 | 7,518 | 9,111 | 5,976 | 6,099 | 6,130 | 6,282 | 6,622 | |
3,379 | 4,134 | 4,763 | 5,141 | 4,493 | 4,510 | 5,995 | 7,367 | 4,428 | 4,695 | 4,980 | 5,503 | 5,775 | |
Operating Profit | 891 | 999 | 999 | 610 | 1,256 | 1,352 | 1,522 | 1,744 | 1,548 | 1,403 | 1,150 | 779 | 847 |
OPM % | 21% | 19% | 17% | 11% | 22% | 23% | 20% | 19% | 26% | 23% | 19% | 12% | 13% |
-318 | -93 | -173 | 86 | 4 | 19 | 36 | -249 | 225 | 263 | 8 | -9 | 98 | |
Interest | 238 | 311 | 337 | 368 | 371 | 341 | 284 | 220 | 200 | 184 | 145 | 188 | 255 |
Depreciation | 221 | 254 | 281 | 288 | 347 | 291 | 415 | 371 | 340 | 349 | 382 | 554 | 552 |
Profit before tax | 114 | 341 | 207 | 40 | 542 | 738 | 859 | 904 | 1,233 | 1,133 | 630 | 28 | 138 |
Tax % | 60% | 45% | 34% | 200% | 29% | 22% | 26% | 36% | 27% | 26% | 34% | 334% | |
46 | 189 | 138 | -40 | 387 | 575 | 634 | 577 | 898 | 836 | 413 | -65 | 34 | |
EPS in Rs | 0.91 | 9.59 | 6.84 | -3.63 | 24.60 | 36.14 | 40.35 | 36.06 | 56.39 | 52.47 | 25.98 | -3.83 | 2.36 |
Dividend Payout % | 328% | 31% | 43% | -83% | 12% | 8% | 7% | 12% | 9% | 10% | 19% | -130% |
Compounded Sales Growth | |
---|---|
10 Years: | 2% |
5 Years: | -4% |
3 Years: | 2% |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -38% |
Stock Price CAGR | |
---|---|
10 Years: | 15% |
5 Years: | -1% |
3 Years: | -7% |
1 Year: | 105% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 10% |
3 Years: | 6% |
Last Year: | -7% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 16 | 16 | 15 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Reserves | 2,241 | 2,460 | 2,611 | 2,438 | 2,951 | 3,420 | 4,071 | 4,793 | 5,588 | 4,726 | 5,303 | 5,383 | 5,394 |
3,818 | 4,245 | 4,395 | 4,793 | 4,493 | 4,045 | 3,469 | 4,840 | 4,808 | 2,830 | 3,192 | 3,677 | 3,668 | |
1,688 | 1,650 | 1,842 | 1,372 | 1,280 | 1,417 | 1,902 | 1,670 | 1,898 | 1,192 | 1,319 | 1,853 | 2,322 | |
Total Liabilities | 7,763 | 8,371 | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,400 |
4,460 | 4,967 | 5,099 | 4,911 | 5,104 | 5,107 | 5,401 | 5,648 | 6,340 | 4,609 | 4,871 | 5,183 | 5,989 | |
CWIP | 686 | 437 | 472 | 597 | 611 | 684 | 671 | 901 | 768 | 897 | 1,090 | 1,561 | 1,095 |
Investments | 19 | 26 | 34 | 40 | 85 | 103 | 124 | 115 | 69 | 241 | 239 | 256 | 266 |
2,598 | 2,941 | 3,259 | 3,071 | 2,939 | 3,006 | 3,262 | 4,654 | 5,133 | 3,017 | 3,631 | 3,928 | 4,050 | |
Total Assets | 7,763 | 8,371 | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,400 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
707 | 970 | 772 | 783 | 1,099 | 1,268 | 1,303 | 1,122 | 1,543 | 1,784 | 838 | 661 | |
-596 | -504 | -164 | -362 | -309 | -465 | -614 | -1,018 | -267 | -727 | -323 | -474 | |
-889 | -450 | -414 | -503 | -843 | -686 | -901 | 657 | -1,050 | -1,709 | -33 | -157 | |
Net Cash Flow | -778 | 17 | 194 | -82 | -52 | 117 | -212 | 761 | 225 | -652 | 482 | 30 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 56 | 50 | 51 | 52 | 60 | 63 | 55 | 51 | 79 | 49 | 55 | 56 |
Inventory Days | 231 | 198 | 200 | 169 | 207 | 223 | 177 | 147 | 463 | 268 | 308 | 268 |
Days Payable | 190 | 115 | 107 | 99 | 106 | 137 | 145 | 106 | 273 | 124 | 139 | 160 |
Cash Conversion Cycle | 97 | 133 | 144 | 122 | 162 | 149 | 87 | 92 | 268 | 194 | 224 | 165 |
Working Capital Days | 50 | 40 | -16 | 45 | 52 | 66 | 57 | 65 | 105 | 78 | 86 | 77 |
ROCE % | 11% | 12% | 11% | 6% | 13% | 15% | 15% | 16% | 15% | 12% | 10% | 3% |
Documents
Announcements
- Board Meeting Outcome for Change In Independent Directors Of The Company 2d
-
Announcement under Regulation 30 (LODR)-Change in Management
2d - Change in Independent Directors of the Company.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
2d - Change in Independent Directors of the Company
- Closure of Trading Window 22 Mar
- Announcement under Regulation 30 (LODR)-Credit Rating 22 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Feb 2024TranscriptNotesPPT
-
Oct 2023TranscriptNotesPPT
-
Jul 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptPPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptPPT
-
Jun 2022TranscriptPPT
-
Mar 2022TranscriptNotesPPT
-
Jan 2022TranscriptPPT
-
Jul 2021TranscriptPPT
-
Jun 2021Transcript PPT
-
Jan 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
Jun 2020Transcript PPT
-
Jan 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Oct 2018TranscriptPPT
-
Jul 2018TranscriptPPT
-
Jun 2018TranscriptNotesPPT
-
May 2018TranscriptPPT
-
Jan 2018TranscriptPPT
-
Oct 2017TranscriptPPT
-
Aug 2017TranscriptNotesPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
Jul 2016TranscriptPPT
-
May 2016TranscriptPPT
-
Jan 2016TranscriptPPT
Business Segment FY23
a. Radiopharma (~40%): Radiopharmaceuticals (including radiopharmacies)
b. Allergy Immunotherapy (~10%): Allergy Therapy products
c. Contract Development and Manufacturing Organisation - Sterile Injectables (18%): Contract manufacturing of Sterile Injectables and Non-Sterile products
d. Generics (12%): Solid Dosage Formulations
e. Contract Research, Development, and Manufacturing Organisation (19%): (i) Drug discovery services and (ii) Active Pharmaceutical Ingredients
f. Proprietary Novel Drugs (~1%): Patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases. [1]